P2X7-dependent immune pathways in retinal diseases. (1st February 2023)

• Record Type: Journal Article
• Authors: Déchelle-Marquet, Paul-Alexandre; Guillonneau, Xavier; Sennlaub, Florian; Delarasse, Cécile
• Is Part Of: Neuropharmacology. Volume 223(2023)
• Publication Date: 2023-02-01
• Subjects: P2X7 -- Retina -- Age-related macular degeneration -- Uveitis -- Macrophage -- Microglia; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2022.109332
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: Adenosine triphosphate (ATP) is a signalling molecule acting as a neurotransmitter but also as a danger signal. The purinergic receptor P2X7 is the main sensor of high concentration of ATP released by damaged cells. In the eye, P2X7 is expressed by resident microglia and immune cells that infiltrate the retina in disease such as age-related macular degeneration (AMD), a degenerative retinal disease, and uveitis, an inflammatory eye disease. Activation of P2X7 is involved in several physiological and pathological processes: phagocytosis, activation of the inflammasome NLRP3, release of pro-inflammatory mediators and cell death. The aim of this review is to discuss the potential involvement of P2X7 in the development of AMD and uveitis. This article is part of the Special Issue on 'Purinergic Signaling: 50 years'. Highlights: Immune pathways are implicated in the pathogenesis of AMD and uveitis. P2X7 is involved in phagocytosis and inflammatory mediators release in the eye. The contribution of P2X7 expressed by MP and/or T-cells on pathophysiologic processes is discussed. Modulation of P2X7 may improve AMD and uveitis.